Havrix Junior

Havrix Junior is a hepatitis A vaccine that contains inactivated hepatitis A virus and algeldrate as excipient. It is supplied in an intramuscular injectable form, marketed in the European Union. The product is prescription‑only and is classified under ATC code J07BC01. Havrix Junior is intended to stimulate active immunity by prompting the body to produce protective antibodies against hepatitis A virus for prevention in children.

Havrix Junior is indicated for the active immunization against hepatitis A infection.

- Primary prevention of hepatitis A in children who have not been previously immunized. - Use in outbreak settings to quickly establish herd immunity among pediatric populations. - Administration as part of a two‑dose schedule recommended by public health authorities. - May be given to travelers aged 1‑15 years who are heading to regions with high hepatitis A endemicity. - Can be used in combination with other routine childhood vaccines when administered at separate injection sites.

The safety profile of Havrix Junior reflects the typical reactions observed with inactivated viral vaccines.

Common: - Mild pain, redness, or swelling at the injection site, usually resolving within a few days. - Low‑grade fever or chills occurring within 24‑48 hours after vaccination. - Transient fatigue, headache, or mild irritability in the days following injection.

Serious: - Severe allergic reaction (anaphylaxis) presenting with difficulty breathing, hives, or swelling of the face. - Guillain‑Barré syndrome, a rare neurological condition characterized by muscle weakness. - High fever or seizures that require medical evaluation.

Before administering Havrix Junior, healthcare providers should review the following precautionary considerations.

- Confirm that the child has no known severe allergy to any vaccine component, including algeldrate. - Defer vaccination in individuals with acute moderate or severe illness until recovery. - Assess history of previous hepatitis A vaccination to avoid unnecessary repeat dosing. - Observe the recipient for at least 15 minutes after injection for immediate hypersensitivity reactions. - Use with caution in children with compromised immune systems, as response may be reduced. - Document any prior episodes of Guillain‑Barré syndrome.

Havrix Junior does not have extensive drug‑drug interaction data, but certain co‑administered agents merit attention.

Avoid: - Concurrent administration of live viral vaccines at the same anatomical site, which may interfere with immune response. - Use of immunoglobulin products within 14 days before or after vaccination, as they can neutralize the antigen.

Use with caution: - Simultaneous receipt of other inactivated vaccines may increase local reactogenicity; monitor for heightened soreness. - Patients receiving immunosuppressive therapy may exhibit a diminished antibody response; consider serologic testing. - Co‑administration with antipyretics such as acetaminophen may mask fever, a common post‑vaccination sign.